Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Reneo Pharmaceuticals, Inc. - Class A Common Stock (NQ:RPHM)

1.820 UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Reneo Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 Next >
News headline image
Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Why Reneo Pharmaceuticals Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Shares of Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) shares rose sharply during Wednesday’s session after Concentra sent an acquisition proposal to acquire 100% of equity of the company for $1.80 per... 
Via Benzinga
News headline image
5 Analysts Have This to Say About Reneo Pharmaceuticals ↗
 
Via Benzinga
News headline image
Why Ascent Industries Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket ↗
Shares of Ascent Industries Co. (NASDAQ: ACNT) rose sharply in pre-market trading as the company reported the sale of the business of Specialty Pipe & Tube for around $55 million in an all-cash deal.... 
Via Benzinga
News headline image
Nasdaq Turns Lower; US Retail Sales Top Estimates ↗
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning lower on Thursday. The Dow traded up 0.04% to 37,105.00 while the NASDAQ fell 0.44% to 14,669.25. The S&P 500 also... 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Is Genetic Disease Focused Reneo Pharmaceuticals Stock Plummeting Today? ↗
Reneo Pharmaceuticals Inc (NASDAQ: RPHM) shares are sinking after the company released data from its pivotal STRIDE Phase 2b study of mavodelpar in adult patients with primary mitochondrial myopathies... 
Via Benzinga
News headline image
Recap: Reneo Pharmaceuticals Q3 Earnings ↗
 
Via Benzinga
News headline image
Reneo Pharmaceuticals: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
Why Amtech Systems Shares Are Trading Higher By Over 30%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of Amtech Systems, Inc. (NASDAQ: ASYS) shares fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter sales results and issued first-quarter sales... 
Via Benzinga
News headline image
Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results
Topline data results from the pivotal STRIDE study are expected in December 2023 
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Reneo Pharmaceuticals Announces Poster Presentation at Upcoming Scientific Meetings
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Reneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
Topline data results from the STRIDE study are expected in December 2023 
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Reneo Pharmaceuticals to Participate in the Jefferies Biotech CNS/Neuro Summit
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023 ↗
 
Via Benzinga
News headline image
Reneo Pharmaceuticals Reports Second Quarter 2023 Financial Results
Topline results of the STRIDE study, the pivotal mavodelpar clinical trial in adult patients with primary mitochondrial myopathies (PMM) due to mitochondrial DNA (mtDNA) defects, anticipated in 4Q23 
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 3, 2023 ↗
 
Via Benzinga
News headline image
Reneo Pharmaceuticals to Participate in SVB Securities Therapeutics Forum
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Reneo Pharmaceuticals Added to Russell 2000® and Russell 3000® Indices
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Reneo Pharmaceuticals Announces Presentation and Posters at Mitochondrial Medicine Symposium 2023
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Update -- Reneo Pharmaceuticals to Participate at the Jefferies Healthcare Conference
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Reneo Pharmaceuticals to Participate at the Jefferies Healthcare Conference
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Over $65M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying ↗
Although US stocks closed mixed on Wednesday, there were a few notable insider trades. 
Via Benzinga
News headline image
Reneo Pharmaceuticals Reports First Quarter 2023 Financial Results
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.